Pain Reports最新文献

{"title":"Optimising clinical trial methods for complex regional pain syndrome: a methodological framework (OptiMeth-CRPS).","authors":"Keith M Smart, Victoria Abbott-Fleming, Frank Birklein, Stephen Bruehl, Erica Corcoran, Simon Day, Michael C Ferraro, Sharon Grieve, Ralf-Dieter Hilgers, Carolyn Ingram, David J Keene, Franz König, Candida McCabe, Stavros Nikolakopoulos, Neil E O'Connell","doi":"10.1097/PR9.0000000000001320","DOIUrl":"10.1097/PR9.0000000000001320","url":null,"abstract":"<p><strong>Introduction: </strong>Complex regional pain syndrome (CRPS) is a rare, disabling pain disorder. Systematic reviews have identified a critical lack of high-quality clinical trial evidence to inform the management of CRPS. There is an urgent need to find solutions to the methodological challenges of undertaking clinical trials in CRPS. The aim of this project was to develop a methodological framework for optimising future clinical trials in CRPS (OptiMeth-CRPS).</p><p><strong>Methods: </strong>An international network with expertise in the lived experience of CRPS, CRPS trials and evidence synthesis, and rare disease trial methods developed the framework using an \"Experience and expertise\" approach through an iterative process of (1) online and face-to-face meetings, (2) reviewing and approving meeting notes, and (3) revising draft manuscripts to develop the framework.</p><p><strong>Results: </strong>The OptiMeth-CRPS methodological framework presents 9 key optimisation strategies for improving the methodological quality of CRPS trials. These include strategies for optimising (1) the trial team, (2) research questions, (3) trial governance and management, (4) trial design, (5) the trial population, (6) intervention and comparator groups, (7) trial outcomes, (8) data analysis, and (9) openness, transparency, and reporting. We highlight those optimisation strategies that specifically address the challenges of undertaking clinical trials in people with CRPS.</p><p><strong>Conclusion: </strong>A methodological framework for optimising clinical trials in CRPS has been developed. The OptiMeth-CRPS methodological framework may support the CRPS research community to undertake high-quality clinical trials and improve the quality of the evidence on which clinical decisions and guidelines for the management of CRPS are based.</p>","PeriodicalId":52189,"journal":{"name":"Pain Reports","volume":"10 6","pages":"e1320"},"PeriodicalIF":4.3,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503147/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145253772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Eyelid heat pain sensitivity in healthy participants.","authors":"Nicholas J Pondelis, Vanda Faria, Hailey Krasnikov, Cameron Talbert, Madison Dudek, Paula A Sepulveda-Beltran, David Valdes-Arias, David Zurakowski, Anat Galor, Scott Holmes, Elizabeth R Felix, Eric A Moulton","doi":"10.1097/PR9.0000000000001337","DOIUrl":"10.1097/PR9.0000000000001337","url":null,"abstract":"<p><strong>Introduction: </strong>Chronic ocular pain (COP) is a widespread pain condition that presents clinical challenges, has heterologous and overlapping etiologies across patients, and can have a debilitating effect on quality of life. It can manifest with neuropathic-like symptoms as well as dysesthesias associated with afferent disruption, brain dysfunction, or both, complicating diagnosis and treatment. Quantitative sensory testing (QST) has been used extensively in individuals with chronic pain to detect abnormal peripheral and central nervous system function. Investigating relevant sensory thresholds is crucial for integrating QST into ocular pain assessments.</p><p><strong>Objectives: </strong>This study aimed to determine heat pain thresholds on the eyelid in healthy participants. Furthermore, we sought to evaluate the eyelid as a feasible and suitable body site for COP investigation using QST.</p><p><strong>Methods: </strong>Heat pain thresholds were measured in 80 healthy participants at 2 study sites using the method of limits at 3 stimulation sites: the upper eyelid, the forehead, and the volar forearm.</p><p><strong>Results: </strong>Analysis revealed a significantly lower estimated marginal mean (EMM) heat pain threshold on the eyelid (42.5 ± 0.4 EMM ± SE) compared with the forehead (46.6 ± 0.4 EMM ± SE) (<i>P</i> < 0.001) and forearm (46.4 ± 0.4 EMM ± SE) (<i>P</i> < 0.001). These differences were statistically significant regardless of sex, study site, or age. No differences were found between the forehead and the forearm (<i>P</i> = 1.00).</p><p><strong>Conclusion: </strong>The eyelid is a clinically relevant site for QST in the investigation of ocular and trigeminal function, and this study sets the groundwork for applying eyelid QST in future research of ocular pain and disease etiology.</p>","PeriodicalId":52189,"journal":{"name":"Pain Reports","volume":"10 5","pages":"e1337"},"PeriodicalIF":3.1,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12456492/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145139525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-lasting and fast methylglyoxal-scavenging peptide CycK(Myr)R₄E alleviates chronic pain in type 2 diabetic mice.","authors":"Paramita Basu, Diogo F S Santos, Nina Gakii, Margaret R Gralinski, Ryan B Griggs, Sebastian Brings, Thomas Fleming, Keiichiro Susuki, Bradley K Taylor","doi":"10.1097/PR9.0000000000001312","DOIUrl":"10.1097/PR9.0000000000001312","url":null,"abstract":"<p><strong>Introduction: </strong>Pathological levels of methylglyoxal (MG), a reactive dicarbonyl product of glucose, contribute to major neurological complications associated with type II diabetes, including chronic neuropathic pain. Strategies to target elevated MG have included small molecule MG scavengers, but scavenger deficiencies in proteolytic stability and onset of scavenging activity have precluded clinical translation. To address this gap, we developed a long-lasting and highly reactive cyclic peptide CycK(Myr)R₄E, and here evaluated its antihyperalgesic efficacy in the db/db mouse model of type II diabetes painful diabetic neuropathy.</p><p><strong>Objectives: </strong>To test the hypothesis that CycK(Myr)R₄E can reduce behavioral and molecular signs of painful diabetic neuropathy.</p><p><strong>Methods: </strong>We assessed heat hypersensitivity as an index of hyperalgesia, and touch-evoked expression of phosphorylated extracellular signal-regulated kinase as a measure of neuronal activity in spinal cord dorsal horn.</p><p><strong>Results: </strong>We report that a single systemic injection of CycK(Myr)R₄E (3 mg/kg) reversed heat hypersensitivity. Repeated systemic injection of CycK(Myr)R₄E (0.125 mg/kg, 3 times per week, 6-12 weeks of age) prevented heat hypersensitivity and reduced stimulus-evoked phosphorylated extracellular signal-regulated kinase.</p><p><strong>Conclusion: </strong>These studies promote CycK(Myr)R₄E as the most promising MG scavenger for the prevention and treatment of hyperalgesia in type 2 diabetic neuropathic pain.</p>","PeriodicalId":52189,"journal":{"name":"Pain Reports","volume":"10 5","pages":"e1312"},"PeriodicalIF":3.1,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12348387/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144849595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validation of the menstrual sensitivity index in adolescents.","authors":"Laura C Seidman, Ariel B Handy, Laura A Payne","doi":"10.1097/PR9.0000000000001315","DOIUrl":"10.1097/PR9.0000000000001315","url":null,"abstract":"<p><strong>Introduction: </strong>The Menstrual Sensitivity Index (MSI), assessing the attunement to and fear of menstrual symptoms, was recently developed and validated in an adult sample.</p><p><strong>Objectives: </strong>The objective of this study was to validate the MSI in adolescents.</p><p><strong>Methods: </strong>One hundred forty-one girls aged 13 to 19 participated in a larger parent study on primary dysmenorrhea, and their data were used in the present study. Girls participated at 2 timepoints: baseline (N = 141) and a 1-year follow-up (N = 115). At each timepoint, participants completed the MSI and a variety of self-report measures.</p><p><strong>Results: </strong>A confirmatory factor analysis supports the previously identified factors of the MSI (somatic anxiety, fear/danger, and medication) in adolescent girls. The MSI demonstrates good item-total correlations, internal consistency, and test-retest reliability. The MSI converged most strongly with pain catastrophizing and diverged most strongly from body pain.</p><p><strong>Conclusion: </strong>The MSI is a valid and reliable measure of attunement to and fear of menstrual symptoms in adolescents. Unlike research in adult women demonstrating convergence between the MSI and menstrual pain and menstrual symptom severity, the divergence between the MSI and these variables in the current study suggests that, for adolescents, menstrual sensitivity is more strongly related to fear of pain than menstrual pain itself. These findings provide considerations for future research and clinical practice addressing menstrual pain and symptoms in adolescents.</p>","PeriodicalId":52189,"journal":{"name":"Pain Reports","volume":"10 5","pages":"e1315"},"PeriodicalIF":4.3,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12333772/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144818192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pain when it \"counts\": hurdle analysis of clinical pain ratings improves data model performance.","authors":"Beth B Hogans, Bernadette C Siaton, John D Sorkin","doi":"10.1097/PR9.0000000000001322","DOIUrl":"10.1097/PR9.0000000000001322","url":null,"abstract":"<p><strong>Objectives: </strong>The Numerical Rating Scale is widely used for patient-reported appraisals of pain intensity; however, scale properties have limited utility for assessing chronic pain. Specifically, single pain ratings demonstrate high intraindividual variability. We propose an efficient alternative, termed hurdle analysis, separately analyzing zero and nonzero pain ratings.</p><p><strong>Methods: </strong>This retrospective study of 23,480 US Veterans diagnosed with low back pain (LBP) included 2.1 million unique pain ratings. Marginal distributions comprised of all pain ratings for each individual were parametrized with usual and hurdle analysis methods to holistically assess scale utilization.</p><p><strong>Results: </strong>The population was 87% male and 13% female; 41% Black, 38% White, and 2% Hispanic; modal age range was 65 years to 84 years (45 years-64 years) for men (women). Focusing on statistically informative records, ie, those with ≥100 pain ratings (22% of the total), the median [interquartile range] pain rating was 3.5 [2.3-4.7] (4.0 [3.0-5.1]) for men (women). Marginal distributions were non-normal, with zero being the modal value in 79% (73%) of men (women). In hurdle analysis, the average proportion of zeroes was 0.39 (0.31) for men (women); the average nonzero pain rating was 5.9 [5.1-6.6] (6.0 [5.3-6.7]) for men (women). The nonzero averages, in contrast to standard averages, were normally distributed for the population and compared with data showed less bias and variance.</p><p><strong>Conclusion: </strong>Analysis of clinical pain ratings from Veterans with LBP with hurdle analysis yielded improved estimates of pain when-pain-is-present (ie, nonzero pain) and also demonstrated the variable presence of pain in this population. Further study of this approach appears warranted.</p>","PeriodicalId":52189,"journal":{"name":"Pain Reports","volume":"10 5","pages":"e1322"},"PeriodicalIF":3.1,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12333713/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144818190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validity and contributions to pain from the central aspects of pain questionnaire in rheumatoid arthritis.","authors":"Stephanie Louise Smith, Vasileios Georgopoulos, Onosi Sylvia Ifesemen, Richard James, Eamonn Ferguson, Richard J Wakefield, Deborah Wilson, Philip Buckley, Dorothy Platts, Susan Ledbury, Ernest Choy, Tim Pickles, Zoe Rutter-Locher, Bruce Kirkham, David Andrew Walsh, Daniel F McWilliams","doi":"10.1097/PR9.0000000000001295","DOIUrl":"10.1097/PR9.0000000000001295","url":null,"abstract":"<p><strong>Introduction: </strong>The central nervous system (CNS) contributes to pain perception across musculoskeletal conditions. The central aspects of pain (CAP) questionnaire captures a single score associated with quantitative sensory testing (QST) evidence of CNS dysfunction validated in knee osteoarthritis.</p><p><strong>Objectives: </strong>Given the different pathophysiology of rheumatoid arthritis (RA), an inflammatory polyarthritis, this cross-sectional study assessed CAP's psychometric properties and its association with pain in RA.</p><p><strong>Methods: </strong>Adults with RA were recruited from Nottinghamshire, London, and Cardiff. Participants completed CAP and reported pain using a numerical rating scale. A subgroup underwent additional assessments, including quantitative sensory testing (QST; Pressure Pain detection Threshold, Temporal Summation, Conditioned Pain Modulation), Disease Activity Score-28, C-reactive protein, questionnaires addressing pain and related characteristics, and Central Sensitization Inventory short form (CSI-9). Cronbach alpha, confirmatory factor (CFA), and Rasch measurement theory assessed CAP's reliability and validity. Multivariable linear regression modelled contributions to pain by inflammation indices and CAP or CSI-9.</p><p><strong>Results: </strong>The 380 participants (73% female, median 63 years) reported average pain over the past 4 weeks of 6/10 and a CAP score of 9/16. Central aspects of pain demonstrated acceptable reliability (ICC_(2,1) = 0.71), CFA fit (comparative fit index = 0.99, Tucker-Lewis index = 0.99, root mean square error of approximation = 0.034, standardized root mean residuals = 0.03), and internal consistency (α = 0.82). Central aspects of pain was significantly associated with pain (0.50 ≤ β ≤ 0.57) but not QST. Central aspects of pain explained 33% of pain variance, rising to 42% with inflammation, age, sex, and body mass index. Central Sensitization Inventory-9 correlated with pain, not QST and explained less pain variance than CAP.</p><p><strong>Conclusion: </strong>Central aspects of pain is reliable and valid for use with people with RA and explains RA pain variance better than inflammation or CSI-9.</p>","PeriodicalId":52189,"journal":{"name":"Pain Reports","volume":"10 4","pages":"e1295"},"PeriodicalIF":3.1,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12185087/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144477787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Brivaracetam for spinal cord injury-related neuropathic pain: results of a pilot double-blinded, randomized, placebo-controlled clinical trial.","authors":"Leslie R Morse, Ricardo A Battaglino, Nguyen Nguyen, Brian DeVries, Abigail Welch, Ana Lucia Battaglino, Clas Linnman, Michael Stillman, Robert Wudlick, Joda Glossner, Grant Anderton, Richard Goldstein, Scott P Falci","doi":"10.1097/PR9.0000000000001301","DOIUrl":"10.1097/PR9.0000000000001301","url":null,"abstract":"<p><strong>Objective: </strong>Assess feasibility, safety, and tolerability of 3 months of oral brivaracetam for severe (9-10/10) spinal cord injury-related neuropathic pain.</p><p><strong>Methods: </strong>We conducted a multisite pilot study where adults were randomized to 3 months of brivaracetam (100 mg BID) or placebo. Pain was assessed via the Brief Pain Inventory, the International Spinal Cord Injury Pain Basic Dataset (version 2.0), and a daily pain diary.</p><p><strong>Results: </strong>We enrolled 24 participants across 2 sites and 14 participants were included in the final analysis (n = 8 placebo, n = 6 brivaracetam). The drug was tolerated with expected, nonserious side effects (nausea if taken on an empty stomach, fatigue that improved after 2-3 days). Side effects were more common in the brivaracetam group (73%, n = 8 vs 33%, n = 3). We observed a mean 2.7-point reduction in daily worst pain in the brivaracetam group compared to a 1.0-point reduction in the placebo group. The percentage of participants experiencing 30% (100% vs 60%) and 50% (60% vs 12.5%) pain reduction was greater in the brivaracetam group.</p><p><strong>Conclusions: </strong>These findings suggest safety, tolerability, and feasibility of brivaracetam for treating neuropathic pain in spinal cord injury. These pilot findings will be used to power future efficacy clinical trials.</p>","PeriodicalId":52189,"journal":{"name":"Pain Reports","volume":"10 4","pages":"e1301"},"PeriodicalIF":3.1,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12173286/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144318672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sensory neuron-specific block of multifaceted sodium channels mitigates neuropathic pain behaviors of osteoarthritis.","authors":"Seung Min Shin, Brandon Itson-Zoske, Hao Xu, Hongfei Xiang, Fan Fan, Quinn H Hogan, Hongwei Yu","doi":"10.1097/PR9.0000000000001288","DOIUrl":"10.1097/PR9.0000000000001288","url":null,"abstract":"<p><strong>Objective: </strong>Multiple voltage-gated sodium channels (Na_Vs) in the peripheral sensory neurons (PSNs) regulate action potentials and their dysfunction contributes to the pain pathogenesis of osteoarthritis (OA). A combined block of multiple Na_V subtypes selectively in the PSNs may, therefore, represent an effective analgesic approach in OA painful neuropathy.</p><p><strong>Methods: </strong>To test this hypothesis, we generated recombinant adeno-associated virus (AAV) encoding a potent Na_V inhibitory peptide aptamer, termed Na_ViPA1, that has a multipronged feature of inhibiting tetrodotoxin-sensitive Na_V1.7, 1.6, 1.1, and 1.3, characterized in our recent report. Adeno-associated virus-encoded Na_ViPA1 was delivered into the ipsilateral lumbar 4/5 dorsal root ganglia of rats 2 weeks after induction of knee monoiodoacetate-OA (MIA-OA) and evoked and spontaneous sensory behaviors were followed in 6 weeks.</p><p><strong>Results: </strong>Expression of Na_ViPA1 selective in the PSNs produced significant and comparable mitigations of evoked and spontaneous pain behavior and reversal of weight-bearing asymmetry in both male and female MIA-OA rats. Whole-cell current-clamp recordings showed that AAV-mediated Na_ViPA1 expression normalized action potential firing of the PSNs from MIA animals, suggesting that Na_ViPA1 attenuated pain behavior by, at least in part, reversing neuronal hyperexcitability.</p><p><strong>Conclusion: </strong>Together, these results support that (1) Na_Vs in peripheral sensory pathways contribute to MIA-OA pain pathogenesis and (2) Na_ViPA1 is a promising analgesic lead that, combined with AAV-targeted delivery to pathological sensory ganglia, may be a viable peripherally selective PSN-targeting strategy in mitigating chronic MIA-OA pain behaviors.</p>","PeriodicalId":52189,"journal":{"name":"Pain Reports","volume":"10 4","pages":"e1288"},"PeriodicalIF":3.1,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12119052/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144182329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond single targets: leveraging degeneracy in sodium channels for osteoarthritis analgesia.","authors":"Samantha Perez-Miller, Rajesh Khanna","doi":"10.1097/PR9.0000000000001289","DOIUrl":"10.1097/PR9.0000000000001289","url":null,"abstract":"<p><p><b>Commentary on:</b> Shin SM, Itson-Zoske B, Xu H, Xiang H, Fan F, Hogan QH, Yu H. Sensory neuron-specific block of multifaceted sodium channels mitigates neuropathic pain behaviors of osteoarthritis. Pain Rep 2025. DOI: 10.1097/PR9.0000000000001288.</p>","PeriodicalId":52189,"journal":{"name":"Pain Reports","volume":"10 4","pages":"e1289"},"PeriodicalIF":4.3,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12119048/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144182341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pain in women: bridging the gender pain gap.","authors":"William Laughey, Katy Vincent, Samyuktha Iyer, Maria M Cobo, Rebeccah Slater","doi":"10.1097/PR9.0000000000001276","DOIUrl":"10.1097/PR9.0000000000001276","url":null,"abstract":"<p><p>Bridging the gender pain gap requires collaborative efforts that address female-specific biological and psychosocial dimensions of pain through evidence-based, compassionate and empathy-driven approaches.</p>","PeriodicalId":52189,"journal":{"name":"Pain Reports","volume":"10 3","pages":"e1276"},"PeriodicalIF":3.1,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12094398/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144121472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}